Skip to main content
Powered by ShareScore

Find research datasets worth reusing

Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.

660

datasets available to search

ShareScore release 0.9.0

Reset

Dataset results

660 results for “antitumor”

Learn how ShareScore rates datasets ↗
zenodo40/100

Dataset related to article "NKp46-expressing human gut-resident intraepithelial Vδ1 T cell subpopulation exhibits high antitumor activity against colorectal cancer"

<p>&gamma;&delta; T cells account for a large fraction of human intestinal intraepithelial lymphocytes (IELs) endowed with potent antitumor activities. However, little is known about their origin, phenotype, and clinical relevance in colorectal cancer (CRC). To determine &gamma;&delta; IEL gut specificity, homing, and functions, &gamma;&delta; T cells were purified from human healthy blood, lymph nodes, liver, skin, and intestine, either disease-free, affected by CRC, or generated from thymic precursors. The constitutive expression of NKp46 specifically identifies a subset of cytotoxic V&delta;1 T cells representing the largest fraction of gut-resident IELs. The ontogeny and gut-tropism of NKp46+/V&delta;1 IELs depends both on distinctive features of V&delta;1 thymic precursors and gut-environmental factors. Either the constitutive presence of NKp46 on tissue-resident V&delta;1 intestinal IELs or its induced expression on IL-2/IL-15-activated V&delta;1 thymocytes are associated with antitumor functions. Higher frequencies of NKp46+/V&delta;1 IELs in tumor-free specimens from CRC patients correlate with a lower risk of developing metastatic III/IV disease stages. Additionally, our in vitro settings reproducing CRC tumor microenvironment inhibited the expansion of NKp46+/V&delta;1 cells from activated thymic precursors. These results parallel the very low frequencies of NKp46+/V&delta;1 IELs able to infiltrate CRC, thus providing insights to either follow-up cancer progression or to develop adoptive cellular therapies.</p> <p>&nbsp;</p> <p>This dataset is created with fcs files form, in order to guarantee the access we attach a pdf information about</p>

opencc-by-4.0Mar 2020View details →
zenodo40/100

A fungal-derived adjuvant amplifies the antitumoral potency of BCG

<p>A repository of data for the mouse single-cell multiome (RNA+ATAC) dataset of lineage negative bone marrow samples pre- and post- treatment BCG or b-glucan treated mice.</p>

opencc-by-4.0May 2024View details →
zenodo36/100

Recombinant Costimulatory Fusion Proteins as Functional Immunomodulators Enhance Antitumor Activity in Murine B16F10 Melanoma

<p>Cancer immunotherapy has emerged as an important therapeutic modality in preclinical and clinical oncology. Blocking inhibitory signaling and engaging stimulatory signaling enable some patients to produce an efficient antitumor response. In this work, we demonstrate unique and unexpected immunomodulatory features of different costimulatory ligand proteins with no combination of tumor-associated products, which bridge innate and adaptive immune responses against cancer in preventive as well as therapeutic efficacy.</p>

opencc-by-4.0Apr 2020View details →
dryad36/100

Identification of a small molecule Tim-3 inhibitor to potentiate T cell-mediated antitumor immunotherapy in preclinical models

<p><span>T cell immunoglobulin and mucin-containing molecule 3 (Tim-3), expressed in dysfunctional and exhausted T cells, has been widely acknowledged as a promising immune checkpoint target for tumor immunotherapy. Here, using a strategy combining virtual and functional screening, we identified a compound named ML-T7 that targets the FG-CC' cleft of Tim-3, a highly conserved binding site of </span><span>phosphatidylserine</span><span> (PtdSer) and carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1). ML-T7 enhanced the survival and antitumor activity of </span><span>primary CD8<sup>+</sup> cytotoxic T lymphocytes (CTLs) and human chimeric antigen receptor (CAR) T cells and reduced their exhaustion </span><span>in vitro and in vivo</span><span>. In addition, ML-T7 promoted NK cells' killing activity and DC antigen-presenting capacity, consistent with the reported activity of Tim-3.</span><span> Notably, ML-T7 strengthened DCs' functions through both Tim-3 and Tim-4, consistent with the hypothesis that Tim-4 contains a similar FG-CC' loop. Intraperitoneal dosing of ML-T7 showed comparable tumor inhibitory effects to Tim-3 blocking antibody. ML-T7 reduced syngeneic tumor progression in both wildtype and Tim-3 humanized mice and alleviated the immunosuppressive microenvironment. Furthermore, combined ML-T7 and anti-PD-1 therapy had greater therapeutic efficacy than monotherapy in mice, supporting further development of ML-T7 for tumor immunotherapy. Our study demonstrates a potential small molecule for selectively blocking Tim-3 and warrants further study.</span></p>

opencc-zeroNov 2023View details →
ClinicalTrials.gov36/100

Pharmacokinetic (PK) Analysis of Antitumor B in Patients With Oral Cancer

ClinicalTrials.gov study NCT03459729. IPD Sharing: NO. Countries: 1. Publications: 1.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov36/100

Study of the Safety, Pharmacokinetics and Antitumor Activities of BGB-A317 in Participants With Advanced Tumors

ClinicalTrials.gov study NCT02407990. IPD Sharing: YES. Countries: 5. Publications: 2.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov36/100

A Dose Escalation, Dose Expansion Study to Evaluate the Safety, Tolerability, and Antitumor Activity of MEDI-575, in Subjects With Advanced Tumors.

ClinicalTrials.gov study NCT00816400. IPD Sharing: Not stated. Countries: 1. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov36/100

Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma

ClinicalTrials.gov study NCT04401800. IPD Sharing: YES. Countries: 1. Publications: 1.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov36/100

Study Investigating Safety, Tolerability, Pharmacokinetics (PK) and Antitumor Activities of Anti-PD-1 (Programmed Death-1) Monoclonal Antibody

ClinicalTrials.gov study NCT04068519. IPD Sharing: YES. Countries: 1. Publications: 2.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov36/100

A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Participants With Select Advanced Malig

ClinicalTrials.gov study NCT02118337. IPD Sharing: YES. Countries: 6. Publications: 1.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov36/100

The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Participants With Advanced Solid Tumors

ClinicalTrials.gov study NCT02660034. IPD Sharing: YES. Countries: 6. Publications: 2.

controlledIPD-YESFeb 2026View details →
dryad36/100

Identification of a small molecule Tim-3 inhibitor to potentiate T cell-mediated antitumor immunotherapy in preclinical models

Open the record for dataset details and reuse information.

publicNov 2023View details →
zenodo32/100

Dataset related to article "Poly(I:C) stimulation is superior than Imiquimod to induce the antitumoral functional profile of tumor-conditioned macrophages."

<p>Macrophage plasticity is the ability of mononuclear phagocytes to change phenotype, function, and genetic reprogramming upon encounter of specific local stimuli. In the tumor microenvironment, Tumor-Associated Macrophages (TAMs) acquire an immune-suppressive and tumor-promoting phenotype. With the aim to re-educate TAMs to antitumor effectors, in this study, we used two immunestimulatory compounds: the TLR7 agonist Imiquimod (IMQ) and the TLR3 agonist Poly(I:C). To better mimic in vitro the response of TAMs, we used Tumor-Conditioned Macrophages (TC-Mϕ) differentiated in the presence of tumor cell supernatants. Our results show that TC-Mϕ respond differently from conventional M2-polarized macrophages. Upon stimulation with IMQ, TC-Mϕ&nbsp;did not upregulate major histocompatibility complex (MHC II) molecules and unexpectedly expressed increased CD206. With both compounds, TC-Mϕ&nbsp;produced higher levels of inflammatory cytokines than M2 macrophages. IMQ and Poly(I:C) differed in the types of regulated genes and secreted mediators. Reflecting their signaling pathways, only IMQ significantly induced IL-1&beta; and IL-6, while only Poly(I:C) stimulated CXCL10, and both upregulated CCL5. Of note, using a novel cytotoxicity assay, Poly(I:C), but not IMQ, was effective in triggering the cytotoxic activity of TC-Mϕ against cancer cells. Overall, the results demonstrate that Poly(I:C) stimulation of TC-Mϕ is superior than IMQ in terms of macrophage re-education toward antitumor effectors.</p>

opencc-by-4.0Mar 2020View details →
zenodo32/100

Stiffness Regulates Breast Cancer Antitumor Immunity via COX2-FGF2 Pathway

<p>The code for spatial analysis done with subset of samples form publication: Bassiouni R, Idowu MO, Gibbs LD, Robila V, Grizzard PJ, Webb MG, Song J, Noriega A, Craig DW, Carpten JD. Spatial Transcriptomic Analysis of a Diverse Patient Cohort Reveals a Conserved Architecture in Triple-Negative Breast Cancer. Cancer Res. 2023 Jan 4;83(1):34-48. doi: 10.1158/0008-5472.CAN-22-2682. PMID: 36283023; PMCID: PMC9812886.</p> <p>&nbsp;</p>

opencc-by-4.0Dec 2023View details →
zenodo32/100

code and datasets for "GP73 reinforces cytotoxic T-cell function by regulating HIF-1α and increasing antitumor efficacy"

<p>We utilized T-cell-specific GP73 knockout mice to establish MC38 and B16 tumor models to investigate the impact of GP73-deficient T cells on tumor growth. Single-cell sequencing was subsequently employed to classify tumor-infiltrating immune cells and assess changes in cytokines and metabolic genes. Through RNA sequencing, real-time quantitative PCR, western blotting, flow cytometry, seahorse analysis, glucose uptake, and lactate secretion assays, we explored how GP73 regulates HIF-1&alpha; to influence T-cell antitumor functionality. Furthermore, we established adoptive transfer experiments to study the ability of GP73-overexpressing T cells to combat tumors. Clinical tumor patient blood samples were collected to assess the relationship between immunotherapy efficacy and T-cell GP73 levels.</p>

opencc-by-4.0Nov 2024View details →
zenodo32/100

Synergistic antitumor interaction of valproic acid and simvastatin and docetaxel in Prostate cancer cells

<p>Synergistic antitumor interaction of valproic acid, simvastatin and docetaxel in prostate cancer cells on cell migration, cell cycle perturbation, apoptosis, 3D cell culture models and stem marker reduction in<em> in vivo</em> model.</p>

opencc-by-4.0Aug 2021View details →
zenodo32/100

Fig. 6 in Abietane diterpenes from the twigs and leaves of Cephalotaxus oliveri Mast. with antitumor activity

Fig. 6. Apoptosis assay of HepG2 cells exposed to metaglyptin A (19) (0, 10, 20, and 30 μM). **p &lt;0.01, compared to control group.

opennotspecifiedJul 2022View details →
zenodo32/100

Fig. 5 in Abietane diterpenes from the twigs and leaves of Cephalotaxus oliveri Mast. with antitumor activity

Fig. 5. Colony formation assay of HepG2 cells exposed to metaglyptin A (19) (0, 10, 20, and 30 μM) for 7 days. *p &lt;0.05, **p &lt;0.01, compared to control group.

opennotspecifiedJul 2022View details →
zenodo32/100

Fig. 2 in Abietane diterpenes from the twigs and leaves of Cephalotaxus oliveri Mast. with antitumor activity

Fig. 2. Key correlations in HMBC (red arrows) and 1H–1H COSY (black bold) of 1–4, 16, 20, and 21. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)

opennotspecifiedJul 2022View details →
zenodo32/100

Fig. 2. 1H–1H in Antitumoral activity of 1,2,4-oxadiazoles compounds isolated from the Neowerdermannia vorwerkii in liver and colon human cancer cells

Fig. 2. 1H–1H COSY and HMBC key correlations of 3-(pyridin-3-yl)-5-(tiophen-3-yl)-1,2,4-oxadiazole (1), 5-(3-methoxyphenyl)-3-(pyridin-3-yl)-1,2,4-oxadiazole (2) and 5-(3-hydroxyphenyl)-3-(pyridin-3-yl)-1,2,4-oxadiazole (3).

opennotspecifiedSep 2022View details →

ScienceDex guides

Understand access before you commit

These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.

Compare curated datasets

Allen Brain Atlas

Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.

allen-brain-atlas
neuroscienceopenDocumentation, web resources, and API references are available online.
Last verified 2026-04-30Open record

Annotated Behaviour and Observability Dataset (ABODe)

ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.

abode-home-cage
behavioral-neuroscienceopenThe DataShare record exposes download links for annotations, documentation, license text, and the zipped per-snippet data directory.
Last verified 2026-04-30Open record

DANDI Archive for NWB datasets

DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.

dandi-nwb
electrophysiologyopenPublished Dandiset metadata and archive endpoints are available through the production DANDI API.
Last verified 2026-04-30Open record

International Brain Laboratory public data

The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.

ibl
behavioral-neuroscienceopenPublic sessions can be searched and loaded from the IBL public data server through ONE.
Last verified 2026-04-29Open record

OpenNeuro

OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.

openneuro
neuroscienceopenPublished datasets are available on demand over the internet.
Last verified 2026-04-29Open record